Singapore launches new program to facilitate biomed industries
27/11/2006 16:47
Singapore today launched new Good Lab Practice (GLP) program to facilitate
growth of biomedical companies and local laboratories.
According to
Standards, Productivity and Innovation Board ( SPRING Singapore), companies in
US$the billion biomedical industry and local labs can now apply for
registration.
The GLP is a quality system that reviews a research facility's
process and conditions in which its non-clinical studies are planned, performed,
monitored, recorded, reported and archived, the SPRING Singapore
said.
Companies which are GLP-compliant will have their non-clinical studies
data accepted in 30 Organization for Economic Cooperation and Development (OECD)
countries, removing the need for expensive retests, and trimming the
time-to-market for new products, the SPRING Singapore said.
"It will speed up
the time-to-market for products discovered in Singapore and help strengthen our
capabilities in transnational research," said Yeoh Keat Chuan, director of
Biomedical Sciences Group, Economic Development Board (EDB).
The new program,
which is supported by the SPRING Singapore and other four government agencies,
will benefit research labs in the pharmaceutical, pesticide, veterinary drug
products and industrial chemicals industries.
Singapore dedicates to boost
the biomedical sciences and chemicals industries. The biomedical sciences sector
is set to grow to 25 billion Singapore dollars (about US$16 billion) by 2015,
while the chemicals industries will be worth 75 billion Singapore dollars (about
US$48 billion) by 2018.
xinhua
|
